Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma

被引:112
作者
Broyde, Adi [1 ,2 ]
Boycov, Olga [2 ,3 ]
Strenov, Yulia [2 ,3 ]
Okon, Elimelech [2 ,3 ]
Shpilberg, Ofer [1 ,2 ]
Bairey, Osnat [1 ,2 ]
机构
[1] Beilinson Med Ctr, Rabin Med Ctr, Inst Hematol, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Beilinson Med Ctr, Rabin Med Ctr, Inst Hematopathol, IL-49100 Petah Tiqwa, Israel
关键词
B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; HISTOLOGIC GRADE; PROLIFERATIVE ACTIVITY; DIFFUSE; CLASSIFICATION; ANTIGEN; KI67; EXPRESSION; MARKERS;
D O I
10.1002/ajh.21406
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Expression of Ki-67, a nuclear antigen protein present in all cycling cells, is used to determine the growth fraction of tumors. The aim of this study was to evaluate the role and prognostic significance of the Ki-67 proliferation index (PI) in non-Hodgkin's lymphoma. Ki-67 was assayed immunohistochemically in tissue samples of 319 patients with newly-diagnosed non-Hodgkin's lymphoma. In 268 patients, the Ki-67 PI was correlated with clinical course and outcome. The mean Ki-67 PI ranged from 26.6% in indolent lymphomas to 97.6% in very aggressive lymphomas (P < 0.001). The index was <45% in 82.8% of indolent lymphomas and >45% in 85% of aggressive lymphomas (AUC = 0.877, P < 0.001). In patients with diffuse large B-cell lymphoma (n = 141), a Ki-67 PI of 70% was found to significantly discriminate patients with good or bad prognosis (AUC 0.65, P = 0.004). Three-year survival was 75% +/- 5.6% in patients with a low Ki-67 index compared with 55.9% +/- 6% in patients with a high index (P = 0.015). In patients with a low IPI (<= 2), 3-year survival was 94% +/- 4% in those with a Ki-67 index <= 70% and 64% +/- 8.1% in those with a higher index (P = 0.002); in patients with bulky disease (>10 cm), the corresponding 3-year survival by Ki-67 index was 100% and 25% +/- 12% (P = 0.012). Our results suggest that the mean Ki-67 PI differs by type of lymphoma. A cut-off value of 45% can help differentiate indolent from aggressive disease. In diffuse large B-cell lymphoma, a cut-off value of 70% can distinguish patients with a good and bad prognosis when combined with other prognostic factors of low IPI score and bulky disease. Am. J. Hematol. 84:338-343, 2009. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:338 / 343
页数:6
相关论文
共 31 条
[1]   Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly [J].
Borre, M ;
Strausbol-Gron, B ;
Nerstrom, B ;
Overgaard, J .
PROSTATE CANCER AND PROSTATIC DISEASES, 1998, 1 (05) :268-275
[2]   Ki67 protein: the immaculate deception? [J].
Brown, DC ;
Gatter, KC .
HISTOPATHOLOGY, 2002, 40 (01) :2-11
[3]   Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium [J].
de Jong, Daphne ;
Rosenwald, Andreas ;
Chhanabhai, Mukesh ;
Gaulard, Philippe ;
Klapper, Wolfram ;
Lee, Abigail ;
Sander, Birgitta ;
Thorns, Christoph ;
Campo, Elias ;
Molina, Thierry ;
Norton, Andrew ;
Hagenbeek, Anton ;
Horning, Sandra ;
Lister, Andrew ;
Raemaekers, John ;
Gascoyne, Randy D. ;
Salles, Gilles ;
Weller, Edie .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :805-812
[4]  
ELMAR E, 2000, EXP CELL RES, V257, P231
[5]  
GERDES J, 1987, LANCET, V2, P448
[6]  
GRIBBEN J.G., 2005, HEMATOLOGY BASIC PRI, P1397
[7]  
GROGAN TM, 1988, BLOOD, V71, P1157
[8]   THE PROGNOSTIC VALUE OF KI67 IMMUNOSTAINING IN NON-HODGKINS LYMPHOMA [J].
HALL, PA ;
RICHARDS, MA ;
GREGORY, WM ;
DARDENNE, AJ ;
LISTER, TA ;
STANSFELD, AG .
JOURNAL OF PATHOLOGY, 1988, 154 (03) :223-235
[9]   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849
[10]  
HERNANDEZ J, 1997, ONCOLOGIST, V4, P235